1192304-43-0

Basic information

• Product Name: N'-benzyl-2'-O,3'-N-(carbonimidoyl)-3'-N-demethyl-erythromycin A
• Synonyms: N'-benzyl-2'-O,3'-N-(carbonimidoyl)-3'-N-demethyl-erythromycin A
• CAS NO: 1192304-43-0
• Molecular Weight: 835.045
• Mol File: 1192304-43-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N'-benzyl-2'-O,3'-N-(carbonimidoyl)-3'-N-demethyl-erythromycin A(CAS DataBase Reference)
• NIST Chemistry Reference: N'-benzyl-2'-O,3'-N-(carbonimidoyl)-3'-N-demethyl-erythromycin A(1192304-43-0)
• EPA Substance Registry System: N'-benzyl-2'-O,3'-N-(carbonimidoyl)-3'-N-demethyl-erythromycin A(1192304-43-0)

Safety Data

• Hazardous Substances Data: 1192304-43-0(Hazardous Substances Data)

Upstream product

• 114-07-8 erythromycin 
• 622-78-6 Benzyl isothiocyanate 
• 992-62-1 N-Demethylerythromycin A 

Relevant articles and documents

N-Substituted-2′-O,3′-N-carbonimidoyl bridged macrolides: Novel anti-inflammatory macrolides without antimicrobial activity

Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess anti-inflammatory properties. These properties are considered fundamental to the efficacy of these three macrolides in the treatment of chronic inflammatory diseases like diffuse panbronchiolitis and cystic fibrosis. However, long-term treatment with macrolide antibiotics presents a considerable risk for promotion of bacterial resistance. We have examined antibacterial and anti-inflammatory effects of a novel macrolide class: N-substituted 2′-O,3′-N-carbonimidoyl bridged erythromycin-derived 14- and 15-membered macrolides. A small focused library was prepared, and compounds without antimicrobial activity, which inhibited IL-6 production, were selected. Data analysis led to a statistical model that could be used for the design of novel anti-inflammatory macrolides. The most promising compound from this library retained the anti-inflammatory activity observed with azithromycin in lipopolysaccharide-induced pulmonary neutrophilia in vivo. Importantly, this study strongly suggests that antimicrobial and anti-inflammatory activities of macrolides are independent and can be separated, which raises development plausibility of novel anti-inflammatory therapeutics.